Compare IRON & MEOH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRON | MEOH |
|---|---|---|
| Founded | 2017 | 1968 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.0B |
| IPO Year | N/A | N/A |
| Metric | IRON | MEOH |
|---|---|---|
| Price | $73.54 | $47.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 9 |
| Target Price | ★ $110.08 | $48.67 |
| AVG Volume (30 Days) | 526.7K | ★ 665.1K |
| Earning Date | 02-26-2026 | 03-05-2026 |
| Dividend Yield | N/A | ★ 1.57% |
| EPS Growth | N/A | ★ 40.35 |
| EPS | N/A | ★ 2.98 |
| Revenue | N/A | ★ $3,569,374,000.00 |
| Revenue This Year | N/A | $1.99 |
| Revenue Next Year | N/A | $12.55 |
| P/E Ratio | ★ N/A | $15.85 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $30.82 | $25.46 |
| 52 Week High | $99.50 | $52.81 |
| Indicator | IRON | MEOH |
|---|---|---|
| Relative Strength Index (RSI) | 41.49 | 54.83 |
| Support Level | $76.00 | $46.66 |
| Resistance Level | $83.93 | $51.94 |
| Average True Range (ATR) | 4.20 | 1.86 |
| MACD | 0.20 | -0.36 |
| Stochastic Oscillator | 13.69 | 26.41 |
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
Methanex Corp manufactures and sells methanol. Its customers use methanol as a feedstock to produce end-products including adhesives, foams, solvents, and windshield washer fluids. The firm also sells its products to the oil refining industry, where the methanol is blended with gasoline to produce a high-octane fuel or blended as a component of biodiesel. It distributes its products through an extensive supply chain that includes the operation of port terminals, tankers, barges, rail cars, trucks, and pipelines. The company generates the majority of its revenue from Europe.